吉西他滨与顺铂新辅助化疗治疗肌层浸润性膀胱癌效果探讨

The Effect of Gemcitabine and Cisplatin in Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer

目的:对吉西他滨与顺铂新辅助化疗治疗肌层浸润性膀胱癌疗效进行分析。方法:2014年11月-2015年11月,选择笔者所在医院肌层浸润性膀胱癌患者40例,对其采取吉西他滨与顺铂新辅助化疗治疗,即给予吉西他滨(800~1000 mg/m2)、顺铂静脉注射(25 mg/m2)新辅助化疗。当患者完成一定疗程的化疗后,结合患者病情变化情况,对其手术方法进行具体选择,以随访记录的方式,分析患者的不良反应,并对化疗前后患者肿瘤最小径、最大径给予对比分析。结果:当患者进行吉西他滨与顺铂新辅助化疗治疗后,完全缓解率为20.0%(8/40),部分缓解率为30.0%(12/40),疾病稳定率为32.5%(13/40),疾病进展率为17.5%(7/40)。患者治疗后的肿瘤最小径、最大径均得到显著改善,差异有统计学意义(P<0.05)。皮疹、脱发、肝肾功能损害等症状较轻。结论:在对肌层浸润性膀胱癌患者进行临床治疗时,对其进行吉西他滨与顺铂新辅助化疗治疗,不仅使肿瘤体积得到明显减小,而且还具有较高的安全性,值得临床推广。

Objective：To Explore the effect of Gemcitabine and Cisplatin in neoadjuvant chemotherapy for muscle invasive bladder cancer.Method：From November 2014 to November 2015,40 patients of muscle invasive bladder cancer in the author＇s hospital were selected,and were treated with Gemcitabine and Cisplatin,namely Gemcitabine（800-1000 mg/m2） intravenous injection,and Cisplatin（25 mg/m2） neoadjuvant chemotherapy.After treatment,the adverse reactions of patients,before and after chemotherapy in tumor patients with the maximum diameter of the path were compared and analyzed.Result：After treatment,the complete remission rate was 20.0%（8/40）,partial response rate was 30.0%（12/40）,stable disease rate was 32.5%（13/40）,the rate of disease progression was 17.5%（7/40）.After treatment of the tumor diameter,the largest diameter were significantly improved,and the difference was statistically significant（P〈0.05）.Skin rash,hair loss,liver function damage symptoms were mild.Conclusion：In the clinical treatment of muscle invasive bladder cancer patients,the effect of Gemcitabine and Cisplatin on tumor volume can not only significantly reduce the tumor size,but also has high safety,worthy of promotion.